AGILON HEALTH INC (AGL) Stock Fundamental Analysis

NYSE:AGL • US00857U1079

0.5 USD
+0.11 (+26.9%)
At close: Feb 25, 2026
0.4707 USD
-0.03 (-5.86%)
Pre-Market: 2/26/2026, 7:10:33 AM
Fundamental Rating

2

AGL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. The financial health of AGL is average, but there are quite some concerns on its profitability. AGL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • AGL had negative earnings in the past year.
  • In the past year AGL has reported a negative cash flow from operations.
  • AGL had negative earnings in each of the past 5 years.
  • AGL had a negative operating cash flow in each of the past 5 years.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

  • With a Return On Assets value of -19.32%, AGL is not doing good in the industry: 81.19% of the companies in the same industry are doing better.
  • With a Return On Equity value of -100.78%, AGL is not doing good in the industry: 76.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -19.32%
ROE -100.78%
ROIC N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • AGL has a worse Gross Margin (0.51%) than 82.18% of its industry peers.
  • AGL's Gross Margin has declined in the last couple of years.
  • AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

5

2. Health

2.1 Basic Checks

  • AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for AGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • AGL has an Altman-Z score of 1.52. This is a bad value and indicates that AGL is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.52, AGL is not doing good in the industry: 60.40% of the companies in the same industry are doing better.
  • There is no outstanding debt for AGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.52
ROIC/WACCN/A
WACC8.92%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 1.08 indicates that AGL should not have too much problems paying its short term obligations.
  • AGL's Current ratio of 1.08 is on the low side compared to the rest of the industry. AGL is outperformed by 62.38% of its industry peers.
  • AGL has a Quick Ratio of 1.08. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
  • AGL has a Quick ratio (1.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B

3

3. Growth

3.1 Past

  • AGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.79%.
EPS 1Y (TTM)-50.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.67% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 8.46% on average over the next years. This is quite good.
EPS Next Y55.28%
EPS Next 2Y31.03%
EPS Next 3Y22.67%
EPS Next 5YN/A
Revenue Next Year2.13%
Revenue Next 2Y6.04%
Revenue Next 3Y8.59%
Revenue Next 5Y8.46%

3.3 Evolution

AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

1

4. Valuation

4.1 Price/Earnings Ratio

  • AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AGL's earnings are expected to grow with 22.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.03%
EPS Next 3Y22.67%

0

5. Dividend

5.1 Amount

  • AGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

AGILON HEALTH INC

NYSE:AGL (2/25/2026, 8:04:00 PM)

Premarket: 0.4707 -0.03 (-5.86%)

0.5

+0.11 (+26.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners68.58%
Inst Owner Change-1.21%
Ins Owners1.92%
Ins Owner Change5.5%
Market Cap207.29M
Revenue(TTM)N/A
Net Income(TTM)-308.46M
Analysts55
Price Target1.01 (102%)
Short Float %6.61%
Short Ratio2.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.76%
Min EPS beat(2)-114.66%
Max EPS beat(2)-68.86%
EPS beat(4)1
Avg EPS beat(4)56.59%
Min EPS beat(4)-114.66%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)6.64%
EPS beat(12)4
Avg EPS beat(12)-1.81%
EPS beat(16)4
Avg EPS beat(16)-22.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.16%
Min Revenue beat(2)-6.13%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)0.91%
Revenue beat(8)2
Avg Revenue beat(8)-1.54%
Revenue beat(12)6
Avg Revenue beat(12)0.25%
Revenue beat(16)10
Avg Revenue beat(16)0.78%
PT rev (1m)0%
PT rev (3m)-6.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-28.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 1
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS14.2
BVpS0.74
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.32%
ROE -100.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.51%
FCFM N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
F-Score4
Asset Turnover3.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.16%
Cap/Sales 0.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z 1.52
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)186.26%
Cap/Depr(5y)133.4%
Cap/Sales(3y)0.87%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.92%
EPS Next Y55.28%
EPS Next 2Y31.03%
EPS Next 3Y22.67%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.09%
Revenue Next Year2.13%
Revenue Next 2Y6.04%
Revenue Next 3Y8.59%
Revenue Next 5Y8.46%
EBIT growth 1Y-8.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.32%
EBIT Next 3Y22.96%
EBIT Next 5Y18.64%
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.25%
OCF growth 3YN/A
OCF growth 5YN/A

AGILON HEALTH INC / AGL FAQ

What is the ChartMill fundamental rating of AGILON HEALTH INC (AGL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to AGL.


Can you provide the valuation status for AGILON HEALTH INC?

ChartMill assigns a valuation rating of 0 / 10 to AGILON HEALTH INC (AGL). This can be considered as Overvalued.


Can you provide the profitability details for AGILON HEALTH INC?

AGILON HEALTH INC (AGL) has a profitability rating of 0 / 10.


What is the earnings growth outlook for AGILON HEALTH INC?

The Earnings per Share (EPS) of AGILON HEALTH INC (AGL) is expected to grow by 55.28% in the next year.